Skip to main content

Table 1 Pharmacokinetic parameters (expressed as mean ± SD) after the intranasal administration of 512 μg budesonide

From: Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations

 

Cmax(ng/ml)

AUCt(h*ng/ml)

AUCi(h*ng/ml)

tmax(h)

Cmax/AUCi(ng/ml)/(h*ng/ml)

t1/2(h)

MRT (h)

Formulation A

0.90 ± 0.33

2.61 ± 1.50

2.91 ± 1.54

0.43 ± 0.18

0.33 ± 0.10

3.79 ± 1.83

5.01 ± 1.40

Formulation B

0.77 ± 0.24

2.24 ± 0.78

2.46 ± 0.77

0.43 ± 0.25

0.32 ± 0.08

2.98 ± 0.42

4.57 ± 0.69

Back to article page

Trials

ISSN: 1745-6215